X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
FBX-101 is an adeno-associated viral serotype rh10 (AAVrh10) gene therapy. It is being evaluated in phase 1/2 clinical trials for the treatment of Krabbe Disease.
Lead Product(s): FBX-101
Therapeutic Area: Genetic Disease Product Name: FBX-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2024
Details:
Forge will help to advance Life Bio’s partial epigenetic reprogramming platform to address aging-related diseases, including its lead program targeting ophthalmic indications by providing cGMP manufacturing and development services for its novel AAV gene therapy platform.
Lead Product(s): Undisclosed
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Life Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 08, 2023
Details:
FBX-101 is an adeno-associated viral serotype rh10 gene therapy which delivers a functional copy of the GALC gene to cells in both the CNS and PNS. It has been shown to functionally correct the central and peripheral neuropathy associated with krabbe.
Lead Product(s): FBX-101
Therapeutic Area: Genetic Disease Product Name: FBX-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 17, 2023
Details:
The partnership will advance Eikonoklastes’ AAV-based gene therapy, ET-101, into clinical trials for the treatment of patients with amyotrophic lateral sclerosis (ALS).
Lead Product(s): ET-101
Therapeutic Area: Neurology Product Name: ET-101
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Eikonoklastes Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership November 29, 2022
Details:
Subjects treated with FBX-101 (AAVrh.10-hGALC) have shown increased galactocerebrosidase (GALC) enzyme activity in plasma and cerebrospinal fluid (CSF), normal white matter myelination and normalization of motor development in two children 90 days and 9 months post-treatment
Lead Product(s): AAVrh.10-hGALC
Therapeutic Area: Genetic Disease Product Name: FBX-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2022
Details:
Forge will provide research-grade and GMP-Pathway plasmid manufacturing services, in addition to adeno-associated viral vector (AAV) process development, scale-up engineering, and cGMP manufacturing services for Ray Therapeutics’ program, RTx-015.
Lead Product(s): RTx-015
Therapeutic Area: Genetic Disease Product Name: RTx-015
Highest Development Status: IND EnablingProduct Type: Large molecule
Recipient: Ray Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 10, 2022
Details:
Forge will provide research-grade and GMP-Pathway plasmid manufacturing services as well as cGMP adeno-associated viral (AAV) process development and scale-up manufacturing services for Myrtelle’s program, Myr-201 (gene therapy delivery of a therapeutic TMPRSS3).
Lead Product(s): AAV-based TMPRSS3 Gene Therapy
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Product Name: Myr-201
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Myrtelle
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 03, 2022
Details:
The Company will use the funding to expand client offerings, including proprietary technologies, manufacturing systems, cell lines, and additional services to bolster its end-to-end manufacturing platform.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Drive Capital
Deal Size: $90.0 million Upfront Cash: Undisclosed
Deal Type: Series C Financing September 12, 2022
Details:
FBX-101 is an adeno-associated viral serotype rh10 (AAVrh.10-hGALC) gene therapy that is typically delivered after a hematopoietic stem cell transplant. FBX-101 delivers a functional copy of the GALC gene to cells in both the central and peripheral nervous system.
Lead Product(s): AAVrh.10-hGALC
Therapeutic Area: Genetic Disease Product Name: FBX-101
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 30, 2022
Details:
Ray-001 is intended for use in treating patients with retinitis pigmentosa (RP). Optogenetics is a promising approach that has the potential to restore useful vision to visually-impaired and blind individuals.
Lead Product(s): Ray-001
Therapeutic Area: Genetic Disease Product Name: Ray-001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Ray Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership March 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
